An observational study in Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms and Neoplasm Recurrence, Local, sponsored by Minia University. Not yet recruiting at 2 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Minia University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Pancreatic Neoplasms by Minia University — 11 open to participants now, 11 under way, 1 of them phase 3. Pancreatic Neoplasms · Minia University.
Among the 13 studies in Pancreatic Neoplasms by Minia University, this one is one of 2 that started in 2026, is one of 3 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 12th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.
Browse Pancreatic Neoplasms studies →11 of the 13 studies in Pancreatic Neoplasms by Minia University are open now, in 1 country. Recruiting first, the newest first:
Minia University · Sites in Egypt
Ages 18–75
Minia University · Sites in Egypt
Ages 18–80
Minia University · Sites in Egypt
Ages 18–75
Minia University · Sites in Egypt
Ages 18–75
Minia University · Sites in Egypt
Ages 18–75
By country, each count listing its studies:
Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 180 is close to the median of 200 across 741 observational studies indexed under Pancreatic Neoplasms.
Median enrollment 100 across the 10 interventional studies, 100 across the 3 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Minia University is the lead sponsor of 373 studies on the registry; 120 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Pancreatic Neoplasms by Minia University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07132541Minia UniversitySaleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) | 2026-11-25 |
| NCT07009119Minia UniversityLaparoscopic Pancreaticoduodenectomy | 2027-02-01 |
| NCT07022015Minia UniversityPredictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy | 2027-03-20 |
| NCT07148830Minia UniversityMesopancreatic Excision for Pancreatic Duct Adenocarcinoma. | 2027-04-01 |
| NCT07946393Minia UniversityPreoperative CA 19-9 and the Pattern and Timing of Recurrence After Pancreatoduodenectomy (Whipple Operation) for Pancreatic Cancer | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 13 studies in Pancreatic Neoplasms by Minia University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Surgery to remove the head of the pancreas (pancreatoduodenectomy, also called the Whipple operation), usually followed by chemotherapy, is the only treatment that offers long-term survival for cancer in the head of the pancreas (pancreatic ductal adenocarcinoma). Even so, the cancer comes back (recurs) in most patients. Where it comes back first (around the operation site, in the liver, in the lining of the abdomen, in the lungs or elsewhere) and how soon it comes back both affect survival, the choice of further treatment and how patients should be followed up.
CA 19-9 is a blood test measured routinely before this operation. A high level is known to be linked with shorter survival, but whether it also predicts where and when the cancer will recur is uncertain and, to the investigator's knowledge, has not been studied in patients treated in Egypt. Jaundice, which is common in these patients, can raise CA 19-9 falsely, so this study uses only CA 19-9 values measured when the blood bilirubin level was close to normal (2 mg/dL or less).
This is a retrospective study of existing medical records. It includes adults who had a Whipple operation for this cancer at the Hepatopancreatobiliary and Surgical Oncology Unit, Liver and GIT Hospital, Minia University, Egypt, between January 2017 and December 2024, with follow-up information from Minia Oncology Centre. No patient will receive any test or treatment for the study, and no care will be changed. Patients will be compared according to their preoperative CA 19-9 level (37 U/mL or less versus more than 37 U/mL).
The two main questions are whether the preoperative CA 19-9 level is linked to (1) the site of the first recurrence and (2) the time from surgery to recurrence. A recurrence will count only when confirmed by scans or biopsy, never by a rising CA 19-9 alone, and it will be classified by independent doctors who do not know the patients' CA 19-9 results. Other questions include recurrence within 6 and 12 months of surgery, survival, and whether CA 19-9 adds useful information to the routine findings available before surgery.
The investigator expects that patients with a high CA 19-9 will more often recur first in the liver or the lining of the abdomen and will recur sooner, whereas patients with a normal level will recur later and more often only near the operation site. The findings may help tailor follow-up after surgery, identify patients who might benefit from chemotherapy before surgery, and identify patients whose cancer is likely to come back only at the operation site, who might be considered for further local treatment.
BACKGROUND AND RATIONALE
Pancreatoduodenectomy followed by adjuvant systemic therapy is the only treatment sequence associated with long-term survival for pancreatic ductal adenocarcinoma (PDAC) of the pancreatic head, yet most patients recur even after a margin-negative resection and completed adjuvant chemotherapy. The site of first failure and its timing carry separate prognostic information. Hepatic and peritoneal failure carry a worse outlook than isolated local recurrence, which may occasionally be amenable to re-resection or stereotactic radiotherapy, and 12 months of recurrence-free survival separates early from late recurrence with markedly different survival after recurrence. Nodal status alters the timing of recurrence without materially altering its anatomical distribution, so this study treats pattern and timing as two separate primary questions.
Serum carbohydrate antigen 19-9 (CA 19-9; sialyl Lewis a) is the only serum biomarker in routine clinical use for this disease, and an elevated preoperative value is consistently associated with shorter overall and recurrence-free survival. Three properties constrain its interpretation: approximately 5-10% of people are Lewis-negative non-secretors who cannot synthesise the antigen; biliary obstruction raises CA 19-9 independently of tumour burden; and no threshold above the conventional upper limit of normal (37 U/mL) has been universally adopted.
Three gaps motivate the study. First, most evidence linking preoperative CA 19-9 to outcome uses composite endpoints (overall or recurrence-free survival) that collapse anatomically and biologically distinct failure events; whether the marker predicts where a patient will fail has been examined in few series and, to the investigator's knowledge, never in an Egyptian or North African population. Second, studies of recurrence pattern have generally treated death without recurrence as non-informative censoring, which misstates absolute risk; a competing-risk formulation is preferable. Third, confounding by obstructive jaundice and biliary drainage is rarely handled by an explicit, pre-specified rule for measuring the exposure. Egyptian practice also differs from the settings that dominate this literature: upfront surgery predominates for resectable disease, obstructive jaundice at presentation is common, preoperative biliary drainage is frequently required, and access to multi-agent adjuvant chemotherapy is variable. Because serum tumour markers are insufficient as a stand-alone criterion for recurrence, and because CA 19-9 is also the exposure, admitting a rising marker as evidence of recurrence would make any finding circular; recurrence therefore requires radiological or histological confirmation throughout.
OBJECTIVES
HYPOTHESES
Among patients who recur, an elevated index CA 19-9 (>37 U/mL) is associated with a higher relative frequency of distant-only first recurrence, particularly hepatic and peritoneal, and a lower relative frequency of local/locoregional-only first recurrence. An elevated index CA 19-9 is associated with a higher subdistribution hazard of recurrence, with an anticipated hazard ratio of approximately 1.8 relative to a normal value. Null hypotheses: the distribution of first-recurrence patterns and the subdistribution hazard of recurrence do not differ across CA 19-9 strata. Hypotheses are directional, but all tests are two-sided at alpha 0.05.
DESIGN, SETTING AND PERIOD
Single-institution, two-site, retrospective observational cohort study with a competing-risk outcome framework. Operative, anaesthetic, laboratory, radiology and synoptic pathology records come from the Hepatopancreatobiliary and Surgical Oncology Unit and the Department of Pathology, Liver and GIT Hospital, Faculty of Medicine, Minia University; adjuvant treatment, surveillance imaging, tumour-marker trends, recurrence documentation and vital status come from Minia Oncology Centre. Operations performed from 1 January 2017 (establishment of the dedicated hepatopancreatobiliary service, from which synoptic pathology and structured operative records are consistently available) to 31 December 2024 are eligible. Follow-up is censored on 31 August 2026, giving every patient at least 20 months of potential observation. Cumulative incidence is reported to 36 months, and beyond 36 months only where at least 15 patients remain at risk. No aspect of clinical care is altered, and no investigation, sample or patient contact is undertaken for the study other than a single vital-status enquiry where approved. The study follows the STROBE statement for cohort studies. The statistical analysis plan (protocol Section 10) is fixed before database lock; any later change will be dated, documented and reported as a post-hoc amendment.
STANDARD OF CARE DURING THE ACCRUAL WINDOW (CONTEXT ONLY; NOT ALTERED BY THE STUDY)
Pancreatic-protocol contrast-enhanced CT, with MRI/MRCP where the CT is equivocal and endoscopic ultrasound with tissue sampling where a diagnosis is required before treatment; CA 19-9 and CEA at diagnosis and, in jaundiced patients, after biliary decompression; preoperative biliary drainage (endoscopic stenting by default) for cholangitis, severe or symptomatic jaundice, anticipated delay to surgery or nutritional optimisation; review at the joint hepatopancreatobiliary and oncology meeting; pancreatoduodenectomy with standard ISGPS lymphadenectomy, with mesopancreatic excision and an artery-first approach where indicated and venous resection where tumour contact precludes a clear plane; axial slicing with multicolour margin inking and synoptic reporting against the AJCC eighth edition dataset, applying the 1 mm rule; referral for adjuvant chemotherapy within 8 to 12 weeks (gemcitabine monotherapy, gemcitabine with capecitabine, or modified FOLFIRINOX in selected fit patients); and surveillance by clinical review, CA 19-9 and contrast-enhanced CT of the chest, abdomen and pelvis every 3 months for 2 years, then every 6 months to 5 years, with additional imaging for symptoms or a rising marker.
EXPOSURE: INDEX PREOPERATIVE CA 19-9
The index value is the last serum CA 19-9 measured within the 30 days preceding operation at a contemporaneous total bilirubin ≤2 mg/dL (≤34 µmol/L), contemporaneous meaning drawn within 72 hours of the CA 19-9 sample. In patients who underwent preoperative biliary drainage it is the post-drainage value satisfying that criterion; pre-drainage values are recorded separately and never used as the exposure. Where several values qualify, the one closest to operation is used; where none qualifies, the patient enters the secondary cohort and is analysed only in sensitivity analysis S2. Assays are electrochemiluminescence immunoassays; the platform, reference interval and reporting limits in force in each calendar year are tabulated, and any change of platform is entered as a covariate in a sensitivity analysis. Values beyond the limits of quantification are assigned that limit, their number is reported, and a multiple-imputation sensitivity analysis is pre-specified. The exposure is analysed in four pre-specified forms:
OUTCOME DEFINITIONS
Pattern of first recurrence (mutually exclusive categories):
Time to recurrence: months from operation to the first imaging study or biopsy demonstrating recurrence; where recurrence is established by comparison across two studies, the date of the later, confirmatory study. Competing event: death from any cause without documented recurrence. Censoring: alive and recurrence-free at last documented contact or at the follow-up cut-off, whichever is earlier. Early, very early and late recurrence: at or before 12 months, at or before 6 months, and after 12 months, respectively.
RECURRENCE ASCERTAINMENT AND BLINDED ADJUDICATION
Every recurrence requires radiological or histological confirmation. Acceptable evidence is: biopsy or cytology showing adenocarcinoma consistent with the resected primary (the procedure date is the recurrence date); an unequivocal new distant lesion on CECT or MRI, new or progressive locoregional soft tissue ≥10 mm, or a new regional nodal mass ≥10 mm in short axis; a previously indeterminate lesion that has unequivocally enlarged on a study performed at least 6 weeks later (the confirmatory study date is the recurrence date); or focal FDG avidity on PET/CT at a compatible site with a structural correlate on CT or MRI. Not acceptable alone: a rising serum CA 19-9, new or worsening symptoms, clinical suspicion, new ascites without corroboration, or postoperative inflammatory change at the operative bed on early imaging. Patients with biochemical progression but no confirmed recurrence are censored at their last recurrence-free imaging study and counted in a pre-specified sensitivity analysis.
Two clinicians independent of the study (a consultant radiologist and a consultant hepatopancreatobiliary surgeon) independently review all surveillance imaging reports, and the images where equivocal, in packets from which every CA 19-9 value has been removed, recording the fact, date and pattern of recurrence. Disagreement on the fact, on the date by more than 30 days, or on the pattern is resolved by a third independent clinician (a consultant medical oncologist) whose decision is final. Agreement on pattern is reported by Cohen's kappa together with the number of cases requiring adjudication. Whether recurrence was first detected on symptom-triggered or scheduled imaging is recorded.
COVARIATES
Collected in six domains, with permitted values and source documents defined in the case report form and data dictionary: demographic and baseline (age, sex, body mass index, ASA class, ECOG performance status, Charlson age-comorbidity index, new-onset versus longstanding diabetes, smoking); presentation (jaundice, peak bilirubin, biliary drainage modality and interval, cholangitis, albumin, C-reactive protein, haemoglobin, neutrophil and platelet counts with derived ratios, CEA); imaging and staging (CT tumour diameter, NCCN resectability category, radiological nodal status); operative (approach, procedure type, extent of lymphadenectomy, venous or arterial resection, pancreatic texture and duct diameter, operative time, blood loss, transfusion, coded surgeon); pathology (tumour size, grade, pT and pN, nodes examined and involved with lymph node ratio, lymphovascular and perineural invasion, margin status with each margin recorded individually, extrapancreatic extension, background PanIN or IPMN); and postoperative and follow-up (complications graded by Clavien-Dindo, the comprehensive complication index and ISGPS/ISGLS definitions, length of stay, adjuvant therapy, surveillance imaging dates and findings, surveillance CA 19-9 values used descriptively only, recurrence details and vital status). Staging follows the AJCC eighth edition, margin assessment the Leeds Pathology Protocol, and lesion measurement RECIST version 1.1.
DATA SOURCES, EXTRACTION AND QUALITY CONTROL
Data are drawn from the operative logbook and theatre register, hospital electronic and paper records, the clinical pathology laboratory information system (including assay platform and reference intervals), the radiology information system and picture archive, the Department of Pathology archive (blocks and slides available for re-review where a synoptic field is missing or internally inconsistent) and the Minia Oncology Centre record. The principal investigator extracts data onto a purpose-built electronic case report form with range checks, permitted-value lists and mandatory fields, in three passes (surgical, pathological and oncological), after a pilot on 15 records. A random 20% of records is extracted independently by a clinician blinded to the investigator's extraction (Cohen's kappa for categorical and intraclass correlation coefficient for continuous variables; a kappa below 0.80 for any key variable triggers re-extraction of that variable across the whole cohort). Every exposure value and every recurrence date undergoes 100% source verification by an independent second reader. Automated logic checks run before lock (operation before recurrence, recurrence before death, a bilirubin for every index CA 19-9, involved nodes not exceeding nodes examined, and no recurrence without a source-document reference); every query is logged and closed, and the dataset is locked before any inferential analysis, with the lock documented by date, file checksum and signature.
SAMPLE SIZE
The cohort is a fixed population: every eligible patient operated within the accrual window is included. Using Schoenfeld's formula with a hazard ratio of 1.8 for CA 19-9 >37 versus ≤37 U/mL, 35% of patients with a bilirubin-qualified value ≤37 U/mL, 75% cumulative recurrence, two-sided alpha 0.05 and 80% power, 100 recurrence events are required (133 patients; 153 allowing 15% attrition). A minimum of 155 analysable patients (approximately 116 events) is the threshold below which inferential analysis will not proceed; this gives 86% power for a hazard ratio of 1.8, and the smallest hazard ratio detectable with 80% power is 1.73. Institutional volume is expected to yield 170 to 190 eligible patients. The study is not powered for modest differences within individual pattern categories or for prediction-model development: power for early recurrence (odds ratio 2.30) is approximately 70%, multivariable models are capped at ten events per variable, penalised estimation is used where a pattern has fewer than 30 events, and no category with fewer than 10 events is modelled. Such findings are reported as estimates with confidence intervals and described as hypothesis-generating.
STATISTICAL ANALYSIS
Analysis populations: the principal population (all eligibility criteria met, bilirubin-qualified index CA 19-9, adjudicated recurrence status) for all primary analyses; the pattern population (adjudicated first recurrence) for the multinomial analysis; the secondary population (no bilirubin-qualified value obtainable) for sensitivity analysis S2 only; and the early-recurrence set (at least 12 months of follow-up or an event within 12 months).
Descriptive analyses: characteristics by CA 19-9 stratum with standardised mean differences rather than p-values; the distribution of the index value on raw and log2 scales with the proportion at each reporting limit; perioperative outcomes, pathology, adjuvant delivery and surveillance completeness by stratum; and follow-up duration by the reverse Kaplan-Meier method.
Primary analysis 1 (pattern): pattern-specific cumulative incidence by the Aalen-Johansen estimator with competing events (recurrence in another category; death without recurrence) at 6, 12, 24 and 36 months, compared across strata by Gray's test; Fine-Gray subdistribution hazard and cause-specific Cox models for each pattern with at least 10 events (Firth penalisation below 30 events), reported together with their interpretive difference; and multinomial logistic regression of pattern among patients who recur (reference: local/locoregional only), adjusted for the confounder set. Categories with fewer than 10 patients are collapsed in a fixed order (lung-only into other-distant-only; other-distant-only into peritoneal-only if still sparse); local/locoregional-only, liver-only and multiple-site categories are never collapsed, and any collapsing is reported.
Primary analysis 2 (timing): cumulative incidence of recurrence of any pattern with death without recurrence as the competing event, by stratum (Gray's test); primary effect estimate the subdistribution hazard ratio for >37 versus ≤37 U/mL from a multivariable Fine-Gray model adjusted for the confounder set, with a cause-specific Cox model fitted in parallel; the hazard ratio per doubling of CA 19-9 with a restricted cubic spline of adjusted hazard ratio against concentration; and restricted mean time to recurrence at 24 months by stratum.
Secondary analyses: multivariable logistic regression for early and very early recurrence in the early-recurrence set; Kaplan-Meier estimation with the log-rank test and multivariable Cox regression for recurrence-free and overall survival; descriptive post-recurrence survival by pattern and stratum; likelihood-ratio tests between nested Cox models and change in Harrell's C-index for CA 19-9 versus the pathological predictors; and the difference in time-dependent area under the curve at 12 and 24 months, with bootstrap confidence intervals, between a preoperative model (age, sex, Charlson age-comorbidity index, CT tumour size, radiological nodal status, resectability category) with and without CA 19-9.
Covariate selection is causal, not statistical. The minimal sufficient adjustment set is age, sex, Charlson age-comorbidity index, obstructive jaundice with preoperative biliary drainage, and year of surgery as a period effect. Pathological variables (pT and tumour size, pN and lymph node ratio, grade, lymphovascular and perineural invasion, margin status) are treated as mediators and are not adjusted for in the primary model; they enter a pre-specified secondary model, the comparison estimating how far the association operates through conventional pathology. Adjuvant chemotherapy receipt and regimen are modelled as a time-varying covariate to avoid immortal time bias, with a 90-day landmark analysis as a check. Postoperative complications and treatment received at recurrence are descriptive only. Stepwise selection and selection on univariable p-values are not used.
Model diagnostics and missing data: proportional hazards assessed by scaled Schoenfeld residuals, with a time-varying coefficient where violated and restricted mean survival time differences at 12 and 24 months if the exposure itself violates the assumption; influential observations by dfbeta, with re-analysis without any observation that changes the primary estimate by more than 15%; variance inflation factor threshold of 5; functional form by martingale residuals. The exposure and primary outcomes are complete in the principal population by construction. For other variables: complete-case analysis below 5% missingness (checked against the imputed result); multiple imputation by chained equations with 20 imputations between 5% and 30% (imputation model including all analysis variables, the Nelson-Aalen cumulative hazard and the event indicator; estimates combined by Rubin's rules); and no imputation above 30%, the variable being reported descriptively only. The missing-at-random assumption is discussed for each imputed variable, with a pattern-mixture sensitivity analysis where missingness is likely to depend on unobserved values.
Pre-specified sensitivity analyses (all reported, whether or not they agree with the primary analysis):
Subgroups, multiplicity and model performance: five pre-specified exploratory subgroups (margin status R0 versus R1; nodal status N0 versus N1/N2; receipt of adjuvant chemotherapy; obstructive jaundice at presentation; grade, well or moderately versus poorly differentiated) are examined by interaction terms and shown in a forest plot. No alpha adjustment is applied between the two primary objectives, which address distinct outcomes; the Benjamini-Hochberg procedure controls the false discovery rate at 5% within the family of pattern-specific hazard models, with unadjusted and adjusted p-values reported; secondary, subgroup, sensitivity and exploratory analyses are not alpha-adjusted and are labelled hypothesis-generating. Discrimination is quantified by Harrell's C-index and time-dependent area under the curve at 12 and 24 months, calibration by predicted versus observed cumulative incidence in deciles of predicted risk, and optimism by bootstrap resampling with 1000 replicates repeating the whole modelling procedure; performance is described as apparent, internally validated performance in a single-centre cohort, with no claim of external validity. Analyses use R version 4.4 or later (survival, cmprsk, riskRegression, prodlim, mstate, rms, mice, maxstat, nnet, timeROC, coxphf, ggplot2) with version-controlled code.
BIAS AND LIMITATIONS
Pre-specified mitigation: selection bias from excluding patients without a bilirubin-qualified value (excluded patients characterised; S2); detection bias from more intensive surveillance of patients with an elevated marker (surveillance completeness reported by stratum; S3 to S5); incorporation bias (imaging or histological confirmation of every event; adjudicators blinded to all marker values); information bias (structured case report form, 20% duplicate extraction, 100% source verification of exposure and primary outcomes, standardised external definitions); immortal time bias (time-varying adjuvant chemotherapy; S6); competing-risk misestimation (Aalen-Johansen and Fine-Gray methods, Kaplan-Meier reserved for composite endpoints); confounding by indication (biliary drainage in the adjustment set); assay drift (platform recorded per year; year of surgery adjusted for); attrition (structured tracing; loss reported by stratum); and overfitting (events-per-variable cap, penalisation, bootstrap optimism correction). Limitations: retrospective single-centre design (association and temporal sequence, not causation; unmeasured confounding such as molecular subtype and circulating tumour DNA status); interval-scheduled imaging, so times to recurrence are upper bounds; lower sensitivity of CT for peritoneal recurrence; non-secretor status inferred rather than genotyped; heterogeneous adjuvant regimens; and limited power for pattern-specific inference.
ETHICS, CONSENT AND DATA PROTECTION
Approved by the Medical Research Ethics Committee / Institutional Review Board, Faculty of Medicine, Minia University (MUFMIRB approval number 2216:10/26, 3 October 2026). The study is conducted in accordance with the Declaration of Helsinki (2013 revision) and Egyptian Clinical Medical Research Law No. 214 of 2020 and its Executive Regulation No. 927 of 2022; no investigational product or device is involved. Individual informed consent is waived because the research involves no more than minimal risk, the waiver does not adversely affect participants' rights or welfare, the research could not practicably be carried out otherwise (a substantial proportion of the cohort is deceased, and requiring consent would introduce severe non-random selection bias among those with the outcome of interest), and a study summary is available to the department and to any surviving patient or family member who enquires. Where a surviving patient or next of kin is telephoned solely to establish vital status, verbal permission is sought at the start of the call and nothing is requested beyond vital status and the fact and date of any recurrence. Each patient receives a sequential study identifier; the analysis dataset contains no name, hospital number, national identification number, address or telephone number. The linkage file is encrypted, accessible only to the principal investigator and destroyed 5 years after publication; data are held on encrypted institutional storage, never on personal devices, personal cloud accounts or removable media; access is logged; and records are retained for 10 years from publication. No individual-level data leave Minia University, no specimens are transferred, and no data are shared with any commercial entity. Access to Minia Oncology Centre records is subject to that centre's institutional permission.
ORGANISATION, FUNDING AND DISSEMINATION
Single-investigator study: the principal investigator holds every study role and is the guarantor of the data and analysis. Four functions are delegated to clinicians independent of the study (two blinded outcome assessors, a blinded adjudicator, and an independent second reader for duplicate extraction and source verification), who take no part in design, analysis, interpretation or reporting. The study is unfunded and uses existing institutional records; the investigator has no financial or non-financial interest in the CA 19-9 assay, any assay manufacturer or any therapy referenced. Results will be submitted for peer-reviewed publication irrespective of their direction, reported according to STROBE, and added to this record within 12 months of database lock. Substantive amendments (eligibility, exposure or primary outcome definitions, primary analysis) will be approved by the ethics committee before implementation and recorded here.
Consecutive adults (18 years or older) who underwent curative-intent pancreatoduodenectomy for histologically confirmed pancreatic ductal adenocarcinoma of the pancreatic head or uncinate process at the Hepatopancreatobiliary and Surgical Oncology Unit, Liver and GIT Hospital, Faculty of Medicine, Minia University, Egypt, between 1 January 2017 and 31 December 2024, with adjuvant treatment and surveillance records held at Minia Oncology Centre. Every pancreatoduodenectomy in the accrual window is screened from the operative logbook, cross-checked against the theatre register and the pathology accession database, with no sampling fraction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults who underwent curative-intent pancreatoduodenectomy for pancreatic ductal adenocarcinoma of the head or uncinate process between 1 January 2017 and 31 December 2024 whose index preoperative serum CA 19-9 was ≤37 U/mL. The index value is the last CA 19-9 within 30 days before surgery drawn within 72 hours of a total bilirubin ≤2 mg/dL and, after preoperative biliary drainage, the post-drainage value. Includes presumed Lewis-negative non-secretors (\<2 U/mL) and normal levels (2-37 U/mL), also reported as separate ordinal strata; non-secretors are removed from this group in sensitivity analysis S1. Reference group for the primary contrast. Surgery and CA 19-9 testing were delivered as routine care; nothing is assigned or changed by the study.
Procedure: Pancreatoduodenectomy · Diagnostic Test: Index preoperative serum CA 19-9
Adults who underwent curative-intent pancreatoduodenectomy for pancreatic ductal adenocarcinoma of the head or uncinate process between 1 January 2017 and 31 December 2024 whose index preoperative serum CA 19-9 (same bilirubin-qualified definition) was \>37 U/mL. Subdivided for descriptive and trend analyses into moderately elevated (\>37-200 U/mL) and markedly elevated (\>200 U/mL) strata. Exposed group for the primary contrast. Surgery and CA 19-9 testing were delivered as routine care; nothing is assigned or changed by the study.
Procedure: Pancreatoduodenectomy · Diagnostic Test: Index preoperative serum CA 19-9
Curative-intent pancreatoduodenectomy (classical Whipple or pylorus-preserving; open or minimally invasive) with standard ISGPS lymphadenectomy, with mesopancreatic excision, an artery-first approach and venous resection where indicated, performed as routine care at the Liver and GIT Hospital, Minia University, between 1 January 2017 and 31 December 2024. Specimens were reported synoptically against the AJCC eighth edition dataset, applying the 1 mm margin rule. The operation is not assigned, scheduled or modified by the study; operative and pathology data are extracted retrospectively from existing records.
Also known as: Whipple procedure, Pylorus-preserving pancreatoduodenectomy
Exposure of interest. Serum CA 19-9 measured during routine preoperative care by electrochemiluminescence immunoassay and retrieved from laboratory records; no sample is taken for the study. Index value: the last CA 19-9 within 30 days before operation with a contemporaneous total bilirubin ≤2 mg/dL (≤34 µmol/L) drawn within 72 hours of the CA 19-9 sample; after preoperative biliary drainage, the post-drainage value meeting this criterion (pre-drainage values are recorded but never used). Where several values qualify, the one closest to surgery is used. Analysed as binary (\>37 vs ≤37 U/mL; primary contrast), ordinal (\<2, 2-37, \>37-200, \>200 U/mL) and continuous (log2\[CA 19-9 + 1\]) variables.
Also known as: Carbohydrate antigen 19-9, Cancer antigen 19-9, Sialyl Lewis a
Anatomical pattern of first recurrence, by index preoperative CA 19-9 group (>37 vs ≤37 U/mL)
First recurrence classified as local/locoregional only, liver only, peritoneal only, lung or other distant only (including para-aortic station 16 nodes), or multiple synchronous sites (two or more categories within 30 days) by two independent clinicians blinded to all CA 19-9 values, with a third blinded adjudicator for disagreement. Recurrence requires radiological or histological confirmation; a rising CA 19-9 alone never counts. Reported as number (%) of patients in each category and as pattern-specific cumulative incidence (Aalen-Johansen; competing events: recurrence at another site and death without recurrence) compared between groups by Gray's test, with Fine-Gray subdistribution and cause-specific hazard ratios for each pattern with ≥10 events and multinomial odds ratios among patients who recur (reference: local/locoregional only).
Time frame: From pancreatoduodenectomy (1 January 2017 to 31 December 2024) to first recurrence; cumulative incidence at 6, 12, 24 and 36 months; up to 116 months (follow-up censored 31 August 2026)
Time to first recurrence, with death without recurrence as a competing event, by index preoperative CA 19-9 group
Months from operation to the first imaging study or biopsy confirming recurrence (date of the confirmatory study when established by interval progression); death without recurrence is a competing event; patients alive and recurrence-free are censored at last documented contact. Primary effect estimate: subdistribution hazard ratio (Fine-Gray) for CA 19-9 \>37 vs ≤37 U/mL, adjusted for age, sex, Charlson age-comorbidity index, obstructive jaundice with preoperative biliary drainage, and year of surgery, with a cause-specific Cox model in parallel. Also reported: cumulative incidence of recurrence by group (Gray's test), hazard ratio per doubling of CA 19-9 (log2 scale) with a restricted cubic spline, and restricted mean time to recurrence at 24 months.
Time frame: From pancreatoduodenectomy to first confirmed recurrence, death or last follow-up; cumulative incidence at 6, 12, 24 and 36 months; up to 116 months (follow-up censored 31 August 2026)
Early recurrence (within 12 months of surgery)
Number (%) of patients with a confirmed first recurrence at or before 12 months after operation, by CA 19-9 group, in the early-recurrence set (patients with at least 12 months of follow-up or an event within 12 months; the number excluded is reported). Association expressed as an adjusted odds ratio with 95% CI from multivariable logistic regression using the primary adjustment set.
Time frame: 12 months after pancreatoduodenectomy
Very early recurrence (within 6 months of surgery)
Number (%) of patients with a confirmed first recurrence at or before 6 months after operation, by CA 19-9 group, in the early-recurrence set. Association expressed as an adjusted odds ratio with 95% CI from multivariable logistic regression using the primary adjustment set.
Time frame: 6 months after pancreatoduodenectomy
Site-specific cumulative incidence of first recurrence
Cumulative incidence (%, 95% CI) of local/locoregional, hepatic, peritoneal, pulmonary and other distant first recurrence, estimated by the Aalen-Johansen method with competing events, overall and across the four ordinal CA 19-9 strata (\<2, 2-37, \>37-200 and \>200 U/mL), with Gray's test and a test for trend across the three producing strata.
Time frame: 6, 12, 24 and 36 months after pancreatoduodenectomy
Recurrence-free survival
Time from operation to confirmed recurrence or death from any cause, by CA 19-9 group: Kaplan-Meier estimates (median and probabilities at 12, 24 and 36 months) compared by the log-rank test, and adjusted hazard ratio with 95% CI from multivariable Cox regression.
Time frame: From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Overall survival
Time from operation to death from any cause, by CA 19-9 group, with vital status from hospital and Minia Oncology Centre records and, where approved, a single telephone enquiry: Kaplan-Meier estimates (median and probabilities at 12, 24 and 36 months) compared by the log-rank test, and adjusted hazard ratio with 95% CI from multivariable Cox regression.
Time frame: From pancreatoduodenectomy to death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Post-recurrence survival
Time from first confirmed recurrence to death from any cause among patients who recur, by recurrence pattern and by CA 19-9 group (Kaplan-Meier median with 95% CI). Presented descriptively because it conditions on a post-baseline event.
Time frame: From first confirmed recurrence to death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Incremental prognostic discrimination of preoperative CA 19-9 for recurrence
Difference in time-dependent area under the ROC curve (bootstrap 95% CI) between a preoperative model of age, sex, Charlson age-comorbidity index, CT tumour size, radiological nodal status and resectability category, and the same model plus CA 19-9; with the change in Harrell's C-index. Reported as apparent and bootstrap optimism-corrected (1000 replicates) internal performance; no external validity is claimed.
Time frame: 12 and 24 months after pancreatoduodenectomy
Prognostic contribution of CA 19-9 relative to established pathological predictors
Likelihood-ratio tests between nested Cox models and change in Harrell's C-index for CA 19-9 versus pathological predictors (pT and tumour size, pN and lymph node ratio, grade, lymphovascular and perineural invasion, margin status), and comparison of the primary and pathology (mediator)-adjusted models to estimate how far the CA 19-9 association operates through conventional pathology.
Time frame: From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Isolated local recurrence and salvage treatment
Number (%) of patients whose first recurrence is local/locoregional only with no distant disease over the following 3 months, by CA 19-9 group, with any salvage treatment received recorded descriptively.
Time frame: From pancreatoduodenectomy to 3 months after first recurrence; up to 116 months (follow-up censored 31 August 2026)
Postoperative complications
Clavien-Dindo grade, comprehensive complication index (0-100), ISGPS-defined postoperative pancreatic fistula (biochemical leak, grade B, grade C), delayed gastric emptying and post-pancreatectomy haemorrhage, ISGLS bile leak, ISGPS chyle leak, and length of hospital stay, by CA 19-9 group. Descriptive context for the primary analyses; not adjusted for in outcome models.
Time frame: From pancreatoduodenectomy to 90 days after surgery
Adjuvant chemotherapy delivery
Number (%) of patients starting adjuvant chemotherapy, regimen (gemcitabine monotherapy, gemcitabine with capecitabine, modified FOLFIRINOX, other) and interval from operation to the first cycle, by CA 19-9 group.
Time frame: From pancreatoduodenectomy to the end of adjuvant treatment, up to 12 months after surgery
Surveillance completeness and detection pathway
Proportion of protocol-scheduled surveillance imaging studies performed (CT of chest, abdomen and pelvis every 3 months for 2 years, then every 6 months to 5 years) and proportion of recurrences first detected on symptom-triggered rather than scheduled imaging, by CA 19-9 group; used to assess detection bias (sensitivity analyses S3 and S5).
Time frame: From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Exploratory data-driven CA 19-9 threshold for early recurrence
CA 19-9 cut-point best separating early (≤12 months) from late recurrence, identified by maximally selected rank statistics with the Hothorn-Lausen exact correction for multiple cut-point testing and compared with published thresholds. Exploratory; labelled as requiring external validation and not presented as a validated cut-off.
Time frame: 12 months after pancreatoduodenectomy
Characteristics and outcomes of patients with CA 19-9 <2 U/mL (presumed Lewis-negative non-secretors)
Baseline characteristics, pattern of first recurrence, time to recurrence and overall survival of patients with an index CA 19-9 below 2 U/mL at total bilirubin ≤2 mg/dL, described separately and compared with patients with 2-37 U/mL. Non-secretor status is inferred from the value, not genotyped.
Time frame: From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Prognostic value of the CA 19-9 to total bilirubin ratio in patients without a bilirubin-qualified CA 19-9
In the secondary cohort (patients meeting every criterion except a CA 19-9 measured at total bilirubin ≤2 mg/dL), subdistribution hazard ratio for time to recurrence per unit of the CA 19-9 to bilirubin ratio, with bilirubin as a covariate (sensitivity analysis S2). These patients are characterised against the principal cohort and never pooled with it.
Time frame: From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Plan to share: No — De-identified individual participant data underlying the published results (the locked analysis dataset with its data dictionary) and the R analysis code will be shared with qualified investigators on reasonable written request, subject to approval by the Minia University Faculty of Medicine Research Ethics Committee and a data-sharing agreement prohibiting re-identification and onward transfer. Direct identifiers (name, hospital number, national identification number, address, telephone number) are never released. No individual-level data will be deposited in an open repository, because the combination of dates, rare pathological features and a single-institution setting carries a residual re-identification risk that an open deposit could not mitigate.
Start is estimated for Dec 2026; primary completion for Apr 2027, 4 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.